Condition deep-dive · 6 min read

Post-stroke recovery adjunct — what supplements actually have evidence

Updated 2026-05-21 · Reviewed by SupplementScore editors · No sponsorships

Post-stroke recovery is rehabilitation-led and secondary-prevention-anchored: antiplatelet therapy (or anticoagulation in atrial-fibrillation-related stroke), statins, blood pressure control, diabetes management, smoking cessation, and intensive physical and occupational rehabilitation. The supplement adjunct picture is narrower than the marketing suggests. Citicoline has the most-studied (though contested) neurorestorative trial base; omega-3 is the best-evidenced cardiovascular adjunct; B-vitamins matter when homocysteine is elevated; vitamin D matters because deficiency is common in the immobile and indoor-bound. Every supplement decision needs to be coordinated with the antithrombotic plan.

Read this first. Most stroke survivors are on antiplatelet (aspirin, clopidogrel) or anticoagulant (warfarin, DOACs) therapy. Several common supplements (high-dose fish oil, ginkgo, garlic, ginseng, vitamin E, turmeric/curcumin, willow bark) have additive antiplatelet effects with documented bleeding-risk implications. Do not start these without discussing with the stroke neurologist or prescriber. Pre-procedure (any planned surgery or invasive procedure) discontinue 1–2 weeks ahead per surgeon guidance.

What actually works in trials

Tier 2 evidence · Neurorestorative (contested)

Citicoline (CDP-Choline)

1000–2000 mg/day oral; trials have used 500–4000 mg ranges

Citicoline has the most-studied trial base in acute and post-stroke recovery. Earlier meta-analyses (Saver 2008) showed signals for global recovery and functional outcomes. The large ICTUS RCT (Dávalos 2012, 2,298 patients) found no significant benefit on the primary outcome in acute stroke. Smaller post-acute and cognitive-recovery trials remain more positive. The net reading: modest cognitive and global-recovery signal in subgroups, contested overall efficacy in unselected populations. The drug is widely used in Europe and Asia for this indication; the US treats it as a supplement.

Tier 1 evidence · Cardiovascular secondary prevention

Omega-3 EPA/DHA (high dose, prescriber-aware)

1–2 g/day combined EPA+DHA for general CV prevention; higher doses in defined contexts

Omega-3 supports the cardiovascular secondary-prevention plan. REDUCE-IT (icosapent ethyl prescription EPA at 4 g/day) showed reduced CV events including stroke in patients on statins with elevated triglycerides — that's a prescription drug, not OTC fish oil. OTC omega-3 at 1–2 g/day is a reasonable adjunct to comprehensive CV prevention. Watch for additive bleeding risk with antiplatelets at very high doses.

Tier 1 evidence · Status-dependent

Vitamin D3 (to 25-OH-D 30–50 ng/mL)

2,000–4,000 IU/day adjusted by 25-OH-D testing

Vitamin D deficiency is very common in stroke survivors (reduced mobility, indoor confinement, often older age). Lower 25-OH-D correlates with worse functional outcomes in observational data. Trial-level repletion data show modest improvements in functional indices and reduced falls. Fall prevention is independently important in the post-stroke population.

Tier 2 evidence · For elevated homocysteine

B-vitamins (folate, B12, B6) — in confirmed hyperhomocysteinemia

5-MTHF 400–800 mcg, methyl B12 500 mcg, P5P 25 mg daily

Hyperhomocysteinemia is more common in stroke populations than the general adult population. The CSPPT trial showed folic acid added to standard care reduced first stroke in hypertensive Chinese adults with low baseline folate. In US-fortified populations, the secondary-prevention benefit is smaller. Test homocysteine and B12 before supplementing.

Tier 2 evidence · Sarcopenia and rehabilitation support

Protein, creatine, vitamin D, leucine — the muscle-protective stack

Protein 1.2–1.6 g/kg/day; creatine 3–5 g/day; HMB 3 g/day in very frail patients

Disuse-related sarcopenia is a major post-stroke risk that compromises rehabilitation outcomes. Protein adequacy (1.2–1.6 g/kg/day in adults during rehabilitation) is the foundation. Creatine monohydrate 3–5 g/day supports lean mass during rehabilitation and has some cognitive trial signals. HMB (β-hydroxy β-methylbutyrate) at 3 g/day has evidence in frail older adults.

Tier 3 evidence · Possibly relevant

Cocoa flavanols (high dose, standardised)

500–900 mg/day standardised flavanols (Mars CocoaVia trial dose)

The COSMOS trial showed modest cardiovascular-mortality benefits with standardised cocoa flavanols. Not a stroke-specific intervention; reasonable adjunct in users seeking additional vascular-supportive nutrition.

What to skip

Ginkgo biloba at chronic supplemental doses — antiplatelet effect adds meaningfully to existing antiplatelet/anticoagulant therapy.
Vitamin E supplementation at high doses in antiplatelet-treated patients — additive bleeding risk; not benefit-positive in stroke trials.
High-dose garlic, ginger, and willow bark as chronic supplements — additive antiplatelet effects.
St. John's wort — many interactions including with warfarin, antihypertensives, and several common post-stroke medications.
"Cerebral circulation" megadose stacks — typically combinations of ginkgo + vinpocetine + huperzine that have variable individual evidence and stack the antiplatelet/CYP risks.
"Brain regeneration" supplement bundles with sub-therapeutic doses of many ingredients — read labels against citicoline trial doses.
Cannabinoids without prescriber awareness — drug interactions with anticonvulsants (sometimes prescribed post-stroke) and many secondary prevention medications.
Phytoestrogens at high doses in women with hormone-receptor-positive cancer history — relevant context for some post-stroke patients.

What to track

Standard post-stroke monitoring: modified Rankin Scale, NIH Stroke Scale, Barthel Index for functional status; cognitive assessment (MoCA), depression screening (PHQ-9). For secondary prevention: blood pressure, LDL-C, HbA1c, INR or DOAC-specific monitoring as indicated. Add 25-OH-D and homocysteine at baseline and at 8–12 weeks of relevant supplementation. CBC and renal function for medication interactions.

Practical quick-start. Confirm secondary-prevention plan with stroke neurology (antithrombotic, statin, BP, diabetes). Test 25-OH-D and supplement to 30–50 ng/mL. Add omega-3 1–2 g/day combined EPA+DHA (with prescriber awareness if on antiplatelets). Ensure protein adequacy 1.2–1.6 g/kg/day during rehabilitation; consider creatine monohydrate 3–5 g/day for lean-mass support. Test homocysteine and B12; supplement B-vitamins if elevated. Discuss citicoline with the neurologist as a cognitive-recovery adjunct.

Educational reference, not medical advice. Post-stroke care is led by stroke neurology and rehabilitation medicine; every supplement choice needs to be coordinated with the antithrombotic and secondary-prevention plan.

Sources

Dávalos A, et al. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (the ICTUS trial). Lancet. 2012;380(9839):349–357. PMID: 22691567
Saver JL. Citicoline: update on a promising and widely available agent for neuroprotection and neurorepair. Rev Neurol Dis. 2008;5(4):167–177. PMID: 19122569
Bhatt DL, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia (REDUCE-IT). N Engl J Med. 2019;380(1):11–22. PMID: 30415628
Huo Y, et al. Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China (CSPPT). JAMA. 2015;313(13):1325–1335. PMID: 25771069
Sahota P, et al. Citicoline for the treatment of acute ischemic stroke: an international, randomised, multicentre, placebo-controlled study. Lancet Neurol. 2013;12(1):20–21. PMID: 23153406
Sesso HD, et al. Effect of cocoa flavanol supplementation for the prevention of cardiovascular disease events: the COSMOS randomized clinical trial. Am J Clin Nutr. 2022;115(6):1490–1500. PMID: 35294510